Lumos Diagnostics Holdings Ltd
ASX:LDX
Intrinsic Value
Lumos Diagnostics Holdings Ltd. engages in the development and manufacture of point-of-care (POC) diagnostics solutions to help healthcare professionals more accurately diagnose and manage medical con... [ Read More ]
The intrinsic value of one LDX stock under the Base Case scenario is 0.132 AUD. Compared to the current market price of 0.055 AUD, Lumos Diagnostics Holdings Ltd is Undervalued by 58%.
Valuation Backtest
Lumos Diagnostics Holdings Ltd
Run backtest to discover the historical profit from buying and selling LDX stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Lumos Diagnostics Holdings Ltd
| Current Assets | 4.3m |
| Cash & Short-Term Investments | 1.4m |
| Receivables | 1m |
| Other Current Assets | 1.9m |
| Non-Current Assets | 18.7m |
| PP&E | 8.2m |
| Intangibles | 10.5m |
| Current Liabilities | 6.2m |
| Accounts Payable | 2.1m |
| Accrued Liabilities | 2m |
| Other Current Liabilities | 2.2m |
| Non-Current Liabilities | 7.6m |
| Long-Term Debt | 7.6m |
Earnings Waterfall
Lumos Diagnostics Holdings Ltd
|
Revenue
|
8.2m
USD
|
|
Cost of Revenue
|
-3.3m
USD
|
|
Gross Profit
|
4.9m
USD
|
|
Operating Expenses
|
-13.8m
USD
|
|
Operating Income
|
-8.9m
USD
|
|
Other Expenses
|
58k
USD
|
|
Net Income
|
-8.8m
USD
|
Free Cash Flow Analysis
Lumos Diagnostics Holdings Ltd
LDX Profitability Score
Profitability Due Diligence
Lumos Diagnostics Holdings Ltd's profitability score is 21/100. The higher the profitability score, the more profitable the company is.
Score
Lumos Diagnostics Holdings Ltd's profitability score is 21/100. The higher the profitability score, the more profitable the company is.
LDX Solvency Score
Solvency Due Diligence
Lumos Diagnostics Holdings Ltd's solvency score is 34/100. The higher the solvency score, the more solvent the company is.
Score
Lumos Diagnostics Holdings Ltd's solvency score is 34/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
LDX Price Targets Summary
Lumos Diagnostics Holdings Ltd
According to Wall Street analysts, the average 1-year price target for LDX is 0.06 AUD .
Shareholder Return
LDX Price
Lumos Diagnostics Holdings Ltd
| Average Annual Return | -58% |
| Standard Deviation of Annual Returns | 52.87% |
| Max Drawdown | -99% |
| Market Capitalization | 26.5m AUD |
| Shares Outstanding | 481 307 008 |
| Percentage of Shares Shorted |
N/A
|
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Lumos Diagnostics Holdings Ltd. engages in the development and manufacture of point-of-care (POC) diagnostics solutions to help healthcare professionals more accurately diagnose and manage medical conditions. The company is headquartered in South Melbourne, Victoria. The company went IPO on 2021-07-05. The firm's solutions help healthcare professionals to accurately diagnose and manage medical conditions. Lumos offers customized assay development and manufacturing services for POC tests and digital reader platforms. The firm's portfolio of product, technology and service offerings include Point-of-care diagnostic products, Point-of-care readers, Commercial services and Manufacturing services. The firm's products include FebriDx and CoviDx. FebriDx is an all-in-one point-of-care test device that can differentiate a viral from bacterial acute respiratory infection. CoviDx is a rapid immunoassay for the detection of the nucleocapsid protein in nasal swabs (NS), oropharyngeal swabs (OP), and nasopharyngeal swabs (NP) from patients suspected of a Coronavirus-19 (COVID-19) infection.
Contact
IPO
Employees
Officers
The intrinsic value of one LDX stock under the Base Case scenario is 0.132 AUD.
Compared to the current market price of 0.055 AUD, Lumos Diagnostics Holdings Ltd is Undervalued by 58%.
You don't have any saved screeners yet
